Evidence map›Paper›PMID 16421127›Full record

ArticleJournal of neurology, neurosurgery, and psychiatry2006

Peripheral neuropathies in Waldenström's macroglobulinaemia.

T Levine, A Pestronk, J Florence, M T Al-Lozi, G Lopate, T Miller, I Ramneantu, W Waheed, M Stambuk, M J Stone and 1 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Journal of neurology, neurosurgery, and psychiatry, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07160270 (Neuropathy in Waldenström's Macroglobulinemia), which is not on this map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07160270 recruitingnot on this mapstarted 2025, after this paper: background citation

Neuropathy in Waldenström's Macroglobulinemia: Pathophysiology, Prognosis and Treatment

Typeobservational_patient_registrySponsorRigshospitalet, DenmarkRan2025 to 2025Enrolled90ConditionsWaldenstrom Macroglobulinaemia, Peripheral Neuropathies
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 93 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. How to Sequence Therapies in Waldenström Macroglobulinemia.Current treatment options in oncology · 2021
    Review
  7. Article
  8. Article
  9. Article
  10. POEMS syndrome: clinical update.Journal of neurology · 2019
    Review
  11. [Haematologica · 2018
    Article
  12. Article
  13. Splenic re-irradiation for waldenstrőm's macroglobulinemia.Radiation oncology (London, England) · 2012
    Article
  14. Article
  15. Article
  16. The neuropathies of Waldenström's macroglobulinemia (WM) and IgM-MGUS.The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques · 2011
    Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

T LevinePhoenix Neurological Associates, AZ, USA.
A Pestronk
J Florence
M T Al-Lozi
G Lopate
T Miller
I Ramneantu
W Waheed
M Stambuk
M J Stone
R Choksi
Phoenix Neurological Associates · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWe sought to determine the prevalence, clinical features, and laboratory characteristics of polyneuropathies in Waldenström's macroglobulinaemia (WM), a malignant bone marrow disorder with lymphocytes that produce monoclonal IgM.

methodsWe prospectively studied 119 patients with WM and 58 controls. Medical history was taken, and neurological examinations, electrodiagnostic tests, and serum studies were performed by different examiners who were blinded to results except the diagnosis of WM.

resultsPolyneuropathy symptoms, including discomfort and sensory loss in the legs, occurred more frequently (p<0.001) in patients with WM (47%) than in controls (9%). Patients with WM had 35% lower quantitative vibration scores, and more frequent pin loss (3.4 times) and gait disorders (5.5 times) than controls (all p<0.001). Patients with IgM binding to sulphatide (5% of WM) had sensory axon loss; those with IgM binding to myelin associated glycoprotein (MAG) (4% of WM) had sensorimotor axon loss and demyelination. Patients with WM with IgM binding to sulphatide (p<0.005) or MAG (p<0.001) had more severe sensory axon loss than other patients with WM. Demyelination occurred in 4% of patients with WM with no IgM binding to MAG. Age related reductions in vibration sense and sural SNAP amplitudes were similar ( approximately 30%) in WM and controls.

conclusionsPeripheral nerve symptoms and signs occur more frequently in patients with WM than controls, involve sensory modalities, and are often associated with gait disorders. IgM binding to MAG or sulphatide is associated with a further increase in the frequency and severity of peripheral nerve involvement. Age related changes, similar to those in controls, add to the degree of reduced nerve function in patients with WM.

Indexed as

AgedAntibodies, MonoclonalCross-Sectional StudiesElectrodiagnosisElectromyographyFemaleFingersHumansImmunoglobulin MMaleMiddle AgedMotor NeuronsNeural ConductionNeurologic ExaminationPeripheral NervesPolyneuropathiesAntibodies, MonoclonalImmunoglobulin M

Identifiers

PMID16421127
PMCPMC2077569
OpenAlexW2139359304

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.